Average Insider

Where insiders trade, we follow

$MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Jon Congleton
CEO
51
Employees
$28.78
Current Price
$1.85B
Market Cap
52W Low$12.59
Current$28.7846.2% above low, 53.8% below high
52W High$47.65

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00--All Sells
Sells25$1,043,099.5038,722
2 monthsBuys12$8,762,797.00369,0002.37:1
Sells315$3,700,560.39139,716
3 monthsBuys12$8,762,797.00369,0002.02:1
Sells322$4,347,460.39162,708
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Apr 17, 2026
Rodman David Malcom
Chief Medical Officer
Sale416$31.33$13,033.28View Details
Apr 13, 2026
Rodman David Malcom
Chief Medical Officer
Sale14,058$26.54$373,086.67View Details
Apr 15, 2026
Rodman David Malcom
Chief Medical Officer
Sale6,348$27.66$175,585.68View Details
Apr 13, 2026
Congleton Jon
Director
Sale15,730$26.83$421,979.27View Details
Apr 9, 2026
Rodman David Malcom
Chief Medical Officer
Sale2,170$27.38$59,414.60View Details
Mar 31, 2026
Congleton Jon
Director
Sale19,364$25.50$493,793.62View Details
Mar 31, 2026
Congleton Jon
Director
Sale55,183$26.54$1,464,474.05View Details
Mar 31, 2026
Congleton Jon
Director
Sale453$27.05$12,254.15View Details
Mar 31, 2026
Karydas Daphne
Director
Sale3,000$25.00$75,000.00View Details
Mar 27, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
Purchase310,700$23.67$7,354,269.00View Details
Mar 30, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
Purchase58,300$24.16$1,408,528.00View Details
Mar 17, 2026
Rodman David Malcom
Chief Medical Officer
Sale417$25.65$10,696.05View Details
Mar 13, 2026
Rodman David Malcom
Chief Medical Officer
Sale253$27.82$7,038.46View Details
Mar 13, 2026
Rodman David Malcom
Chief Medical Officer
Sale3,079$27.37$84,264.53View Details
Mar 13, 2026
Rodman David Malcom
Chief Medical Officer
Sale10,726$25.91$277,922.46View Details
Mar 12, 2026
Rodman David Malcom
Chief Medical Officer
Sale6,348$27.37$173,747.93View Details
Mar 9, 2026
Rodman David Malcom
Chief Medical Officer
Sale2,171$26.84$58,269.64View Details
Feb 17, 2026
Rodman David Malcom
Chief Medical Officer
Sale417$27.59$11,505.03View Details
Feb 12, 2026
Rodman David Malcom
Chief Medical Officer
Sale5,828$28.94$168,634.93View Details
Feb 13, 2026
Rodman David Malcom
Chief Medical Officer
Sale6,348$27.58$175,100.06View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Mar 12, 2026
EPS
Estimated-$0.52
Actual-$0.40
Beat
Revenue
EstimatedN/A
ActualN/A
Feb 18, 2026
EPS
Estimated-$0.57
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Feb 11, 2026
EPS
Estimated-$0.57
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Version: v26.3.33